In the evolving landscape of gastric cancer therapies, significant attention has been drawn to the overexpression of human epidermal growth factor receptor 2 (HER2), which is seen in about 10–20% of gastric cancer cases [166]. Here, ERBB2 is linked to gastric cancer.